Paper Details

  1. Home
  2. Paper Details

[Treatment of new and chronic tuberculous patients with ethambutol and Rifampicin (author's transl)].

Author: Cesarz-FronczykM, PregowskiW, StanczukA, ZnanieckaH

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study comparing chemotherapy regimens containing ethambutol or rifampicin in patients with chronic pulmonary tuberculosis found that rifampicin resulted in a higher negativization rate.
Paper Details　
Original Abstract of the Article :
In patients with chronic pulmonary tuberculosis the results of chemotherapy between drug regimens containing ethambutol or rifampicin were compared. Patients in both groups were randomized selected. After 4 months of chemotherapy negativization was reached to 100% in the RMP-group compared to 80% of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/983179

データ提供：米国国立医学図書館（NLM）

Combating TB: A Tale of Two Anti-Tubercular Drugs

Tuberculosis (TB), like a tenacious desert wind, continues to plague millions worldwide. Effective treatment is crucial in controlling this disease.

This research delves into the effectiveness of two anti-tubercular drugs, ethambutol (EMB) and rifampicin (RMP), in treating both new and chronic cases of TB. The researchers compared the outcomes of chemotherapy regimens containing either EMB or RMP in patients with chronic pulmonary TB.

The study found that patients treated with RMP-based regimens achieved a higher rate of negativization, meaning the elimination of bacteria from the sputum, compared to those treated with EMB-based regimens. When EMB was added to the chemotherapy regimen in chronic patients, a significant improvement in negativization was observed, albeit lower than the rate achieved with RMP. The researchers also found that RMP led to faster sputum conversion to negative compared to EMB. Similar results were observed in patients with newly diagnosed TB.

The Power of Rifampicin: A Key Weapon in the Fight Against TB

This research highlights the significant effectiveness of RMP in treating TB, both in chronic and newly diagnosed cases. It underscores the importance of RMP as a critical component of anti-tubercular therapy.

Navigating the Sands of TB Treatment: Understanding the Options

The desert of TB treatment can be complex and challenging. This research underscores the value of tailoring treatment regimens based on individual needs and the importance of utilizing effective medications like rifampicin.

Dr. Camel's Conclusion

The findings suggest that RMP-based regimens are highly effective in treating TB, particularly in chronic cases. This knowledge is invaluable in guiding treatment decisions and achieving successful outcomes in the battle against this persistent disease. Remember, like a seasoned traveler in the desert, we must adapt our approach and choose the right tools to navigate this complex landscape.
Date :
  1. Date Completed 1976-12-23
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

983179

DOI: Digital Object Identifier

983179

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.